Prescribing information

 

 

 Image showing red blood cells inside a vein with accompanying text saying 'P-selectin plays a key role in multicellular interactions that can lead to vaso-occlusion in sickle cell disease (SCD)'.

P-selectin plays a key role in multicellular interactions that can lead to vaso-occlusion in sickle cell disease (SCD)1

  • In the pro-inflammatory state associated with SCD,
    P-selectin is overexpressed on activated endothelial cells and platelets1
  • This environment can promote the recruitment of white and red blood cells, as well as platelets. As these cells interact via adhesion mediators, such as P-selectin, multicellular clusters are formed in the bloodstream1–3
  • These events can result in VOCs, which reduces or blocks blood flow to organs1–3
 
Diagram showing the complex pathophysiology of vaso-occlusion in SCD involves more than sickled red blood cells.

The complex pathophysiology of vaso-occlusion in SCD involves more than sickled red blood cells2,3

  • ADAKVEO® is the first and only approved selectin blocker that inhibits key cellular interactions in SCD1,2,4
  • ADAKVEO® is a targeted monoclonal antibody that binds to P-selectin on the surface of activated endothelial cells and platelets1
  • The binding of ADAKVEO® to P-selectin blocks interactions among endothelial cells, platelets, red blood cells and white blood cells1
 

Watch this video for a better understanding of how ADAKVEO® plays a key role in multicellular interactions that can lead to VOCs

 

Banner with text: ADAKVEO has been developed for patients with SCD and is the only P-selectin inhibitor that addresses vaso-occlusion.

ADAKVEO® is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Reporting suspected adverse reactions after authorisation of ADAKVEO® is important to understand the safety profile of the treatment for SCD patients.

Indication: ADAKVEO® (crizanlizumab) is indicated for the prevention of recurrent VOCs in patients with SCD who are aged 16 years and over. It can be given as an add-on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate.1

ADAKVEO® has a conditional marketing authorisation and further evidence is awaited.

Abbreviations: HC, hydroxycarbamide; HU, hydroxyurea; SCD, sickle cell disease; VOC, vaso-occlusive crisis.

References

  1. ADAKVEO® Summary of Product Characteristics.  
  2. Stocker JW, et al. Blood. 2013;122(21):970.
  3. Conran N, et al. Hemoglobin. 2009;33(1):1–16
  4. National Heart, Lung, and Blood Institute. SBIR Success Stories. NHLBI funding leads to promising drug candidate to prevent sickle cell pain. Available at: www.nhlbi.nih.gov/grants-and-training/funding opportunities-and-contacts/smallbusiness-program/sbir-success-stories/nhlbi-funding-leads-promising-drug-candidatepreventsickle-cell-pain. Date accessed: March 2021.
Rate this content: 
No votes yet
UK | May 2021 | 104669
×

Ask Speakers

×

Medical Information Request

 

ADAKVEO® has a conditional marketing authorisation and further evidence is awaited.

For more information, refer to the ADAKVEO® ▼ (crizanlizumab) prescribing information available here:  https://www.health.novartis.co.uk/sites/health.novartis.co.uk/files/adak...

Legal Category: POM.

Marketing Authorisation (MA) number, quantities and price: EU/1/20/1476/001  £1,038.00 per 10ml vial

 

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]